Hims & Hers shares plummet on first quarter earnings miss

Hims & Hers reported a Q1 net loss of $92.1 million, or $0.40 per share, versus a $49.5 million profit a year ago, while revenue came in softer than expected. The disappointing results sent shares down nearly 14% to about $25 on Tuesday morning. The print points to weaker operating momentum and a sharp reversal in profitability.

Analysis

The market is treating this as more than a one-quarter miss: the magnitude of the downside suggests investors are questioning whether HIMS still has operating leverage at the growth rate it is capable of producing. The key second-order issue is that telehealth is an acquisition-driven business disguised as subscription revenue; if unit economics weaken even modestly, customer payback periods extend and the model can flip from scalable to cash-intensive very quickly. That matters because the stock had been priced like a premium growth platform, not a consumer health retailer with margin volatility.

The immediate winners are likely larger, better-capitalized digital health and consumer-health platforms that can absorb higher CAC or use this window to poach share through more disciplined pricing. The losers are not just HIMS shareholders; vendors tied to paid acquisition channels and fulfillment partners could see near-term volume pressure if management tightens spend, which can create a second-order deceleration in gross bookings before it shows up in revenue. If the company responds by cutting marketing to defend profitability, expect a lagged hit to new customer cohorts over the next 1-2 quarters.

From a catalyst standpoint, the next 30-90 days matter most: any guidance cut, slower subscriber adds, or evidence of promotional intensity would likely keep the stock under pressure. The longer-term bull case only reasserts itself if management proves that newer categories can reaccelerate repeat behavior without requiring ever-higher spend. Absent that, this remains a classic de-rating setup where the market compresses the multiple before the fundamentals fully stabilize.

The contrarian view is that the move may still be incomplete if consensus has not yet revised lifetime value assumptions lower. However, if management can show that the loss was driven by timing or mix rather than structural CAC inflation, the stock can rebound sharply because the market is already positioned for disappointment. The asymmetry favors waiting for either capitulation or a clean post-earnings stabilization before trying to catch a bottom.

Key Decisions for Investors

• Short HIMS into any intraday bounce over the next 1-2 sessions; target a move toward prior support levels as multiple compression continues, with risk controlled by a tight stop above the post-earnings gap high.
• Buy HIMS put spreads 30-60 days out, financed by selling lower-strike puts only if willing to own on a further washout; this captures the risk of a guidance reset without paying full skew.
• Pair trade: short HIMS vs long a more diversified healthcare platform or broader healthcare ETF for 1-3 months, expressing the view that premium-growth consumer health names should re-rate lower on weakening unit economics.
• If already long, reduce exposure into strength and only re-enter after one of two signals: improved forward commentary on cohort retention or a sustained base for 2-3 weeks with down volume drying up.